Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg hikes target price on Natwest

(Sharecast News) - Analysts at Berenberg hiked their target price on banking group Natwest from 350.0p to 415.0p on Monday following the group's "comprehensively strong" Q2 results last week. Berenberg stated Natwest's results included one fault, noting the bank's guidance for a FY26 return on tangible equity greater than 13% was unchanged, despite a "significantly stronger" starting point for revenues and improved prospects for margins and growth.

"We regard a 14% RoTE as a realistic floor," said Berenberg. "These returns can be complemented by superior growth and capital returns versus key peers, in our view. Partly as a result, we believe that NatWest can comfortably justify a 25% premium to total book value per share (which can grow by circa 12% annually) versus a current valuation of c1.1x TBVps."

The German bank also believe that further market share gains will be likely for the bank, particularly in UK mortgages and commercial banking, and believes NatWest to be well positioned to benefit from improving prospects for UK lending growth.

"We expect circa 3.5% organic annual loan growth during the next three years. Announced acquisitions provide a further circa 1.2% benefit," said Berenberg, which reiterated its 'buy' rating on the stock.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

Berenberg lowers target price on Impax Asset Management
(Sharecast News) - Analysts at Berenberg lowered their target price on Impax Asset Management from 620.0p to 560.0p on Tuesday but noted that outflows had started to slow.
GSK's Arexvy provides protection over three RSV seasons, trial shows
(Sharecast News) - GSK has announced positive results from a phase III trial of its Arexvy RSV vaccine, showing that just one dose of the treatment could help protect older adults at risk of RSV disease over three seasons.
S&U revenue up, profitability a challenge in first half
(Sharecast News) - Motor and property finance specialist S&U reported a mixed first-half financial performance on Tuesday, after group revenue increased 9% year-on-year to £60.4m.
Loungers reports slight slowdown in LFL sales growth
(Sharecast News) - Cosy Club owner Loungers reported a slight slowdown in like-for-like sales growth on Tuesday and a jump in revenue.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.